Inflammation in the tumor-adjacent lung as a predictor of clinical outcome in lung adenocarcinoma.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
08 11 2023
08 11 2023
Historique:
received:
28
10
2022
accepted:
06
10
2023
medline:
9
11
2023
pubmed:
8
11
2023
entrez:
8
11
2023
Statut:
epublish
Résumé
Approximately 30% of early-stage lung adenocarcinoma patients present with disease progression after successful surgical resection. Despite efforts of mapping the genetic landscape, there has been limited success in discovering predictive biomarkers of disease outcomes. Here we performed a systematic multi-omic assessment of 143 tumors and matched tumor-adjacent, histologically-normal lung tissue with long-term patient follow-up. Through histologic, mutational, and transcriptomic profiling of tumor and adjacent-normal tissue, we identified an inflammatory gene signature in tumor-adjacent tissue as the strongest clinical predictor of disease progression. Single-cell transcriptomic analysis demonstrated the progression-associated inflammatory signature was expressed in both immune and non-immune cells, and cell type-specific profiling in monocytes further improved outcome predictions. Additional analyses of tumor-adjacent transcriptomic data from The Cancer Genome Atlas validated the association of the inflammatory signature with worse outcomes across cancers. Collectively, our study suggests that molecular profiling of tumor-adjacent tissue can identify patients at high risk for disease progression.
Identifiants
pubmed: 37938580
doi: 10.1038/s41467-023-42327-x
pii: 10.1038/s41467-023-42327-x
pmc: PMC10632519
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6764Subventions
Organisme : NCI NIH HHS
ID : R37 CA244775
Pays : United States
Organisme : NCI NIH HHS
ID : U2C CA271890
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA214195
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016087
Pays : United States
Informations de copyright
© 2023. Springer Nature Limited.
Références
Nat Commun. 2020 May 8;11(1):2285
pubmed: 32385277
PLoS One. 2012;7(1):e30880
pubmed: 22292069
Medicine (Baltimore). 2015 Aug;94(32):e1337
pubmed: 26266381
Cancer Res. 2005 Sep 1;65(17):7568-72
pubmed: 16140919
Nat Methods. 2018 Aug;15(8):591-594
pubmed: 30013048
N Engl J Med. 2022 May 26;386(21):1973-1985
pubmed: 35403841
Cancer Res. 2009 Nov 15;69(22):8629-35
pubmed: 19887610
Nat Immunol. 2019 Feb;20(2):163-172
pubmed: 30643263
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
J Clin Invest. 2019 Jun 17;129(7):2964-2979
pubmed: 31205032
Nat Med. 2021 Feb;27(2):289-300
pubmed: 33495604
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Clin Cancer Res. 2018 Jul 1;24(13):2984-2992
pubmed: 29463557
Genome Med. 2020 Jul 14;12(1):62
pubmed: 32664994
Nat Commun. 2016 Aug 16;7:12474
pubmed: 27527408
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
Oncotarget. 2017 Jan 24;8(4):7050-7058
pubmed: 27732964
Cell. 2020 Sep 17;182(6):1606-1622.e23
pubmed: 32888429
J Exp Med. 2021 Jun 7;218(6):
pubmed: 33835136
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13537-42
pubmed: 14573703
N Engl J Med. 2015 Jul 16;373(3):243-51
pubmed: 25981554
Nat Cancer. 2023 Jan;4(1):27-42
pubmed: 36581735
Nat Commun. 2023 Nov 8;14(1):6764
pubmed: 37938580
Clin Proteomics. 2016 Oct 27;13:31
pubmed: 27799870
Nat Methods. 2019 Dec;16(12):1289-1296
pubmed: 31740819
Cancer Med. 2021 May;10(9):3139-3152
pubmed: 33818013
Cell. 2021 Jun 24;184(13):3573-3587.e29
pubmed: 34062119
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Cell. 2020 Sep 3;182(5):1232-1251.e22
pubmed: 32822576
J Natl Cancer Inst. 2014 Mar;106(3):dju004
pubmed: 24563515
Cancer Cell. 2022 Jun 13;40(6):656-673.e7
pubmed: 35523176
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Nat Biotechnol. 2018 Dec 03;:
pubmed: 30531897
J Clin Invest. 1997 Oct 15;100(8):2133-7
pubmed: 9329980
J Thorac Oncol. 2020 Oct;15(10):1599-1610
pubmed: 32562873
Cancer. 1953 Sep;6(5):963-8
pubmed: 13094644
JAMA Surg. 2021 Feb 1;156(2):e205601
pubmed: 33355651
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Sci Rep. 2021 Oct 1;11(1):19596
pubmed: 34599262
Nat Commun. 2017 Oct 20;8(1):1077
pubmed: 29057876
J Thorac Cardiovasc Surg. 1975 Oct;70(4):606-12
pubmed: 170482
J Natl Cancer Inst. 2007 Aug 15;99(16):1257-69
pubmed: 17686824
Int J Cancer. 2021 Jan 1;148(1):238-251
pubmed: 32745259
Transl Lung Cancer Res. 2019 Apr;8(2):124-134
pubmed: 31106123
Nat Med. 2007 Mar;13(3):361-6
pubmed: 17334370
J Intern Med. 2021 May;289(5):629-635
pubmed: 33340175
Front Oncol. 2021 Sep 23;11:632571
pubmed: 34631510
Pharmacogenet Genomics. 2006 Aug;16(8):555-63
pubmed: 16847424
F1000Res. 2021 Sep 28;10:979
pubmed: 35814628
Nat Cancer. 2022 Apr;3(4):505-517
pubmed: 35469013
Sci Rep. 2017 Oct 19;7(1):13543
pubmed: 29051570
Bioinformatics. 2015 Jun 15;31(12):2032-4
pubmed: 25697820
J Thorac Oncol. 2022 Mar;17(3):362-387
pubmed: 34808341